Control Bionics Ltd. · ASX:CBL
Control Bionics — Investor Presentation (November 2025)
16 slides from Control Bionics's investor presentation, Nov 13, 2025
Slide 1: Proven neurotech scaling multi-growth global markets
For personal use only Proven neurotech scaling multi-growth global markets INVESTOR P RES ENTATI ON JEREMY STEELE, CEO 13 NOVEMBER 2025 CON TROLBIO NIC S.C OM | ASX: CBL
Slide 2: Investment Highlights: Proven tech. Commercial traction. Global scaling.
INV ES TME NT H IGH LIG HTS Proven tech. Commercial traction. Global scaling. A validated surface electromyography (sEMG) platform delivering real-world outcomes in communication, rehab, and sport — now expanding with global approvals, revenues, and reach. For personal use only • before corporate ov
Slide 3: Core IP and Products
For personal use only Core IP and Products
Slide 4: Our core IP — years of EMG innovation
TECHNOLOGY Our core IP — 20 years of EMG innovation Proven clinical IP that is now smaller, wireless and wearable. For personal use only NEUROEDUCATOR One of the first prototype systems in A wireless, wearable NeuroNode® was Launched in 2023, the NeuroStrip® the NeuroEDUCATOR series was first launch
Slide 5: EMG technology: how it works
TECHNOLOGY EMG technology: how it works Turning neural signals into action. For personal use only An EMG signal is Our patented code detected. creates a “switch” to operate devices Your brain sends a To move your finger, Our core IP uses smart Users can type, generate thought like “move my an electr
Slide 6: Progress
For personal use only Progress
Slide 7: New integration with Apple's Brain–Computer Interface (BCI) protocol
ASSISTIVE COM MUNICATION New integration with Apple’s Brain–Computer Interface (BCI) protocol For personal use only We are now the only company in the world with a commercially available product using Apple's BCI tech. EVOLVING BCI LANDSCAPE POTENTIAL BENEFITS • BCIs connect the nervous system to di
Slide 8: Control Bionics BCI demonstration
ASSISTIVE COM MUNICATION Control Bionics BCI demonstration For personal use only
Slide 9: NeuroNode wholesale: Unlocking scale in a $1B+ global market
ASSISTIVE COM MUNICATION NeuroNode® wholesale: Unlocking scale in a $1B+ global market For personal use only Our fastest near-term growth lever — now scaling in the US with HCPCS-backed wholesale partners. Global partners are expected to be announced by the end of 2025. MARKET OPPORTUNITY PROGRESS •
Slide 10: Real trials. Real gains. Real endorsements.
SPORTS PER FOR MANCE Real trials. Real gains. Real endorsements. Exceptional initial results. Growing demand. Commercial rollout in motion. For personal use only NEUROBOUNCE USA Outstanding results for first athletes with launch customer, Continued Utah Prep Academy, Princeton College and Nets on Fi
Slide 11: Rehab: Trusted by experts. Scaling with innovation.
RE HAB Rehab: Trusted by experts. Scaling with innovation. Japan’s leading stroke rehab centre adopts NeuroStrip® to provide superior outcomes for its patients. For personal use only JAPAN: STROKELAB REHAB CENTRE US & AU: REHAB Coherent Market Insights Dysphagia Management Market-& Forecast 2025-203
Slide 12: Continue to focus on growth, diversification and innovation in FY26
STRATEGIC FOCUS 2026 Continue to focus on growth, diversification and innovation in FY26 For personal use only • Achieve profitability in core markets: Strengthening the US, Australia, and Japan operations to ensure each market achieves EBITDA and cash flow positivity. • Scaling the NeuroNode Busine
Slide 13: FY26 Roadmap
ROADMAP FY26 Roadmap For personal use only Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 German HMV (Medicare Research Results published Consolidation of software equivalent) application partnerships for from initial applications submitted NeuroStrip® NeuroStrip® announced research projects Commence data analysis
Slide 14: Experienced leadership
COR PORAT E PEOPLE Experienced leadership For personal use only BOA RD • Over 20 years experience in accounting, auditing and finance roles in the United States and Australia • Previously held senior finance positions with multi- national ASX-listed and technology start-up entities Shannon Boothroyd
Slide 15: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or
Slide 16: Get In Touch
Get In Touch For personal use only COMPANY I NVE ST OR RE LATI ONS JEREMY ST EELE J OE DU RA K CEO E X E C UT IV E D I RE C TO R & F OU ND E R CO NT R OL BIO NI CS LYN X A DV I SO R S js teele@c ontrolbionic s. com jo e @l y n xa d v is or s.c o m .a u +61 433 229 470 +61 414 465 582 CON TR OLBIO NI
Control Bionics — Investor Presentation (November 2025) on 6ix